GDC-0853 (Synonyms: RG-7845) |
| Katalog-Nr.GC19162 |
GDC-0853 (GDC-0853) ist ein potenter, selektiver, oral verfÜgbarer und nichtkovalenter Bruton's-Tyrosinkinase (Btk)-Inhibitor mit Kis von 0,91 nM, 1,6, 1,3, 12,6 und 3,4 nM fÜr WT Btk und C481S B. C481R-, T474I-, T474M-Mutanten. GDC-0853 hat das Potenzial fÜr die Erforschung von rheumatoider Arthritis und systemischem Lupus erythematodes.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1434048-34-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Fenebrutinib (GDC-0853) is a potent, selective, and noncovalent bruton's tyrosine kinase (Btk) inhibitor with a Ki of 0.91 nM.
References:
[1]. Erickson RI , et al. Bruton's Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in Rats. J Pharmacol Exp Ther. 2017 Jan;360(1):226-238.
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *